Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Financial Impact of a Culturally Sensitive Hispanic Kidney Transplant Program on Increasing Living Donation
Mathur, Amit K. , Ruiz, Richard , Wang, Andrew , Caicedo, Juan Carlos , Gordon, Elisa J.

Mayo Clinic

Transplantation | November 8, 2022 | Volume: 107 | Issue: 4 | Pages: 970-980

10.1097/tp.0000000000004382 | PMID 36346212 Get It

Background. In the United States, Hispanic/Latinx patients receive disproportionately fewer living donor kidney transplants (LDKTs) than non-Hispanic White patients. Northwestern Medicine’s culturally targeted Hispanic Kidney Transplant Program (HKTP) was found to increase LDKTs in Hispanic patients at 1 of 2 transplant programs with greater implementation fidelity. Methods. We conducted a budget impact analysis to evaluate HKTP’s impact on program financial profiles from changes in volume of LDKTs and deceased donor kidney transplants (DDKTs) in 2017 to 2019. We estimated HKTP programmatic costs, and kidney transplant (KT) program costs and revenues. We forecasted transplant volumes, HKTP programmatic costs, and KT program costs and revenues for 2022–2024. Results. At both programs, HKTP programmatic costs had <1% impact on total KT program costs, and HKTP programmatic costs comprised <1% of total KT program revenues in 2017–2019. In particular, the total volume of Hispanic KTs and HKTP LDKTs increased at both sites. Annual KT program revenues of HKTP LDKTs and DDKTs increased by 226.9% at site A and by 1042.9% at site B when comparing 2019–2017. Forecasted HKTP LDKT volume showed an increase of 36.4% (site A) and 33.3% (site B) with a subsequent increase in KT program revenues of 42.3% (site A) and 44.3% (site B) among HKTP LDKTs and DDKTs. Conclusions. HKTP programmatic costs and KT evaluation costs are potentially recoverable by reimbursement of organ acquisition costs and offset by increases in total KT program revenues of LDKTs; transplant programs may find implementation of the HKTP financially manageable.
Author response: A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
Yan, Jianhua , Li, Hongsong , Jiao, Kunli , Yang, Jingchun , Port, Jenna , Wang, Jun , Li, Yi‐Gang , Ding, Yonghe , Lang, Di , Bu, Haisong , Ni, Haibo , Morotti, Stefano , Le, Tai , Clark, Karl J. , Ekker, Stephen C. , Cao, Hung , Zhang, Yuji , Grandi, Eleonora , Li, Zhiqiang , Shi, Yongyong , Glukhov, Alexey V. , Xu, Xiaolei

Mayo Clinic

No container title available | November 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.77327.sa2 Get It

1454 Multiomics and multimodal analysis approach to construct a diffuse large B cell lymphoma atlas of tumor microenvironment for predictive modeling
Mattie, Mike , Perbost, Régis, Turcan, Sarah, Danan, Corinne , Neelapu, Sattva S. , Miklos, David B. , Jacobson, Caron A. , Lekakis, Lazaros J. , Kim, Jenny , Xue, Allen , Miklos, David B , Danan, Corinne, Locke, Frederick L. , Lin, Yi , Ghobadi, Armin , Wang, Zixing , Xue, Allen, Filosto, Simone , Scholler, Nathalie , Galon, Jérôme

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1513-A1513

10.1136/jitc-2022-sitc2022.1454 Get It

689 Preliminary results of a pilot study of intratumoral injection of autologous dendritic cells after high-dose conformal external beam radiotherapy in unreseltable primary liver cancers
Fonkoua, Lionel Aurelien Kankeu , Wang, Panwen , Hallemeier, Christopher L. , Atwell, Thomas D. , Babadi, Elham , Bornschlegl, Svetlana, Guerrico, Anatilde González, Martinez, Kodi, McCoy, Gabrielle, Regan, Kevin M., Shao, Zuoyi , Dietz, Allan B. , Roberts, Lewis R. , Roberts, Lewis R , Dietz, Allan B , Hallemeier, Christopher Leigh , Tran, Nguyen, Mahipal, Amit , Zhang, Henan , Wang, Junwen , Li, Ying , Dong, Haidong , Lin, Yi , Park, Sean S.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A719-A720

10.1136/jitc-2022-sitc2022.0689 Get It

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer
Hecht, J. Randolph, Sandberg, Mark, Wang, Xueyin , Martin, Aaron, Nampe, Daniel , Gabrelow, Grant B. , Li, Chuck, McElvain, Michele , Lee, Wen-Hua , Shafaattalab, Sanam , Martire, Sara , Fisher, F. , Ando, Yuta, Liu, Edwin , Ju, David, Hsin, Jing-Ping, Zampieri, Alexandre, Morelli, Maria Pia , Welling, Theodore H., Patel, Sandip Pravin , Welch, John S. , Go, William Y., Mardiros, Armen, Maloney, David G. , Wong, Lu-Min, Xu, Han , Molina, Julian R. , Ando, Yuta, Liu, Edwin, Ju, David, Simeone, Diane M. , Kopetz, Scott , Borad, Mitesh J. , Garon, Edward B. , Kirtane, Kedar , Locke, Frederick L. , Ng, Eric, Kamb, Alexander

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A242-A242

10.1136/jitc-2022-sitc2022.0229 Get It

77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity
Morelli, Maria Pia , Molina, Julian R. , Hecht, J. Randolph, Welling, Theodore H., Mardiros, Armen, Wang, Xueyin , Danek, Tyler , Gallagher, Shannon , Lozac’hmeur, Ariane, Beutner, Karl R., Welch, John S. , Maloney, David G. , Go, William Y., Patel, Sandip Pravin , Kopetz, Scott , Simeone, Diane M. , Kirtane, Kedar , Borad, Mitesh J. , Garon, Edward B. , Ng, Eric, Gallagher, Shannon

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A83-A83

10.1136/jitc-2022-sitc2022.0077 Get It

Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
Cremer, Paul , Geske, Jeffrey B. , Owens, Anjali , Jaber, Wael A. , Saberi, Sara , Wang, Andrew , Naidu, Srihari S. , Smedira, Nicholas G. , Wang, Qiuqing, Wolski, Kathy , Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Desai, Milind Y. , Cremer, Paul C , Saberi, Sara , Wang, Andrew , Sherrid, Mark , Naidu, Srihari S , Smedira, Nicholas G , Sehnert, Amy J , Nissen, Steven E , Desai, Milind Y , Geske, Jeffrey B , Harb, Serge C. , Sherrid, Mark V. , Schaff, Hartzell V.

Mayo Clinic

Circulation: Cardiovascular Imaging | November 6, 2022 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/circimaging.122.014986 | PMID 36335645 Get It

Background: In the randomized phase 3 VALOR-HCM study (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) of patients with obstructive hypertrophic cardiomyopathy, mavacamten reduced the need for septal reduction therapy. Because mavacamten improves ventricular compliance, this sub-study examined the effects of treatment with this cardiac myosin inhibitor on diastolic function. Methods: Symptomatic obstructive hypertrophic cardiomyopathy patients on maximally tolerated medical therapy referred for septal reduction therapy were randomized 1:1 to mavacamten or placebo. At baseline and week 16, a resting and stress echocardiogram was performed with interpretation by a core laboratory. In this exploratory substudy, the principal end point was the change in parameters used to define the grade of diastolic function in patients treated with mavacamten and placebo. A related objective was to assess the proportion of patients with an improvement in diastolic function grade. A secondary aim was to assess for correlation between diastolic function parameters and the secondary end points from VALOR-HCM: New York Heart Association class, quality of life, and cardiac biomarkers. Results: Diastolic dysfunction grade was evaluable in 98 patients at baseline and week 16. Among patients treated with mavacamten, 29.4% (15 of 51) demonstrated improvement in diastolic function grade compared with 12.8% (6 of 47) patients with placebo ( P =0.05). Average E/e’ ratio decreased significantly in patients treated with mavacamten (−3.4±5.3) compared with placebo (0.57±3.5; P <0.001). Indexed left atrial volumes (mL/m 2 ) also decreased significantly in patients who received mavacamten (−5.2±7.8) compared with placebo (−0.51±8.1; P =0.005). After adjustment for change in left ventricular outflow tract gradient and mitral regurgitation, mavacamten was significantly associated with a decrease in average E/e’ ratio and indexed left atrial volumes. Change in average E/e’ ratio was significantly correlated with the secondary end points from VALOR-HCM. Conclusions: In this exploratory substudy, after 16 weeks of therapy, mavacamten improved diastolic function, and this change correlated with improvement in clinical and biomarker end points. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
Desai, Milind Y. , Owens, Anjali , Geske, Jeffrey B. , Wolski, Kathy , Saberi, Sara , Wang, Andrew , Cremer, Paul , Naidu, Srihari S. , Smedira, Nicholas G. , McErlean, Ellen, Sewell, Christina , Balasubramanyam, Aarthi, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Sherrid, Mark , Cremer, Paul C , Naidu, Srihari S , Smedira, Nicholas G , Schaff, Hartzell , Sewell, Christina , Sehnert, Amy J , Nissen, Steven E , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Schaff, Hartzell V.

Mayo Clinic

Circulation | November 6, 2022 | Volume: 147 | Issue: 11 | Pages: 850-863

10.1161/circulationaha.122.062534 | PMID 36335531 Get It

Background: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM. Methods: A double-blind randomized placebo-controlled multicenter trial at 19 US sites included patients with oHCM on maximal tolerated medical therapy referred for SRT with left ventricular outflow tract gradient ≥50 mm Hg at rest or provocation (enrollment, July 2020–October 2021). The group initially randomized to mavacamten continued the drug for 32 weeks, and the placebo group crossed over to dose-blinded mavacamten from week 16 to week 32. Dose titrations were based on investigator-blinded echocardiographic assessment of left ventricular outflow tract gradient and left ventricular ejection fraction. The principal end point was the proportion of patients proceeding with SRT or remaining guideline eligible at 32 weeks in both treatment groups. Results: From the 112 randomized patients with oHCM, 108 (mean age, 60.3 years; 50% men; 94% in New York Heart Association class III/IV) qualified for week 32 evaluation (56 in the original mavacamten group and 52 in the placebo cross-over group). After 32 weeks, 6 of 56 patients (10.7%) in the original mavacamten group and 7 of 52 patients (13.5%) in the placebo cross-over group met SRT guideline criteria or elected to undergo SRT. After 32 weeks, a sustained reduction in resting left ventricular outflow tract gradient (−33.0 mm Hg [95% CI, −41.1 to −24.9]) and Valsalva left ventricular outflow tract gradient (−43.0 mm Hg [95% CI, −52.1 to −33.9]) was observed in the original mavacamten group. A similar reduction in resting (−33.7 mm Hg [95% CI, −42.2 to −25.2]) and Valsalva (−52.9 mm Hg [95% CI, −63.2 to −42.6]) gradients was quantified in the cross-over group after 16 weeks of mavacamten. After 32 weeks, improvement by ≥1 New York Heart Association class was observed in 48 of 53 patients (90.6%) in the original mavacamten group and 35 of 50 patients (70%) after 16 weeks in the cross-over group. Conclusions: In severely symptomatic patients with oHCM, 32 weeks of mavacamten treatment showed sustained reduction in the proportion proceeding to SRT or remaining guideline eligible, with similar effects observed in patients who crossed over from placebo after 16 weeks. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
NS2NS: Self-Learning for Seismic Image Denoising
Liu, Naihao , Wang, Jiale , Gao, Jinghuai , Yu, Kai , Lou, Yihuai , Pu, Yitao , Chang, Shaojie

Mayo Clinic

IEEE Transactions on Geoscience and Remote Sensing | November 3, 2022 | Volume: 60 | Issue: No issue available | Pages: 1-11

10.1109/tgrs.2022.3217289 Get It